Group items tagged

Bas Vorsteveld has been elected as the new president of PAGB, the trade association representing the manufacturers of branded OTC medicines, self care medical devices and food supplements. Vorsteveld, who is vice president and general Manager of Haleon GB and Ireland, succeeds Neil Lister, managing director UK & Ireland and vice president at Perrigo. PAGB said the appointment comes at a crucial time for the consumer healthcare association as it looks to expand the role of self-care, secure a long-term favourable business environment for members, adapt to environmental challenges and continue to deliver excellent services for members. "We are so pleased to welcome Bas to the role of President. Bas has been actively involved with PAGB as a board member and we're looking forward to continuing our work with him. I have already seen from Bas's time on our Board that he combines great sector knowledge with drive, energy and genuine passion for what we do and we're so excited to have him as our President," Michelle Riddalls, chief executive of PAGB, said. "Bas's input and guidance as our strategy evolves over the coming years will be vital as we respond to new challenges as they emerge and make the most of the opportunities ahead."

Department of Health and Social Care (DHSC) has issued a medicine supply notification for Oxcarbazepine (Trileptal) 300mg and 600mg tablets on Wednesday (14 June). It has notified that the Oxcarbazepine (Trileptal) 300mg tablets will be out of stock from late June 2023 until mid-July 2023 and Oxcarbazepine (Trileptal) 600mg tablets are out of stock until mid-July 2023. However, generic oxcarbazepine 300mg and 600mg tablets remain available and will be able to support increased demand. "Oxcarbazepine (Trileptal) 150mg tablets and generic oxcarbazepine 150mg tablets remain available but cannot support the increase in demand," said DHSC. "Oxcarbazepine (Trileptal) 60mg/ml oral suspension remains available but cannot meet an increase in demand."

The British Generic Manufacturers Association (BGMA) has raised concerns over the rise in the VPAS rate for 2023 to 26.5 per cent. The Department of Health Social Care (DHSC) today announced that the 2019 voluntary scheme payment percentage for 2023 will be 26.5%. The 2019 voluntary scheme for branded medicines pricing and access is an agreement between the Department of Health and Social Care, NHS England and the Association of the British Pharmaceutical Industry. BGMA believes that the high VPAS tax for 2023 risks more medicines shortages, rising prices for the NHS via reduced competition, and new medicine launches to the UK being deferred. Mark Samuels, Chief Executive of BGMA, said: "Raising the VPAS tax to 26.5% will damage the UK's medicines supply because it will make some products lossmaking. It is more than a five-fold tax increase from 2021, and no industry can cope with this unpredictable and exceptional tax volatility.

Dermal fillers, also known as injectable facial fillers, can be an effective way to reduce the appearance of wrinkles and fine lines, restore facial volume, and enhance certain features. While dermal fillers are generally safe, it's important to know about the potential benefits and side effects before you decide if they're right for you. In this blog post, we will look at the potential benefits and side effects of dermal fillers. We will also provide some tips for preparing for your treatment and ensuring a safe, successful procedure. So if you're considering dermal fillers, read on to learn more! HOW ARE DERMAL FILLERS INJECTED? Dermal fillers are typically injected directly into the skin with a small needle. Your doctor or injector will decide how much filler should be used and where it should be placed based on your desired outcome. In general, people who want to reduce wrinkles or enhance certain features may need more filler than those who just want to restore the volume in their face. Since they are injected under the skin, dermal fillers are minimally invasive and require little downtime after the procedure. It usually takes around 30 minutes to perform the procedure. Additionally, you may experience some swelling, bruising, and tenderness in the area where the filler was injected. This should subside over the next few days.

Light Wheelchair designed to suit every type of disabled people.Choose from traditionally designed wheelchairs available in lightweight and ultra-lightweight models, or peruse our line of fully-featured power wheelchairs, available in travel sizes and heavy duty configurations. We also carry transport chairs sized for both adult and pediatric use, as well as wheelchairs suitable for use in the shower and toilet. Wheelchair athletes, we have what you're looking for, too - check out our sports wheelchairs and get yourself a brand new rig that's perfect for hand cycling, basketball, or tennis! Safe, modern, clean, comfortable, stylish and NHS approved wheelchairs Easy to fold, light weight and will fit in most modern cars Fitted with user brakes and removable footrests Wide range of wheelchair seat sizes to suit most users Light Wheelchair Light Wheelchair is an immense upgrade, over a heavy wheelchair that can cause your condition to worsen and may also lead to further physical problems. In the last decade wheelchairs that are lightweight and foldable have become the norm in industry.lightweight wheelchairs covers a wide range of conditional needs and lifestyle options that may cater to you. Although not as light as an ultra light wheelchair, this series offers many advantages over generic wheelchairs, they are easier to fold and often more portable. Features- Foldable Aluminium (Light weight) Rear wheel to wheel width in open position (inches) : 20" Upholstery: Cloth look like, washable Armrest: Flip up, for easy transfer to bed Legrest: Flip up footplate Wheel Quality: Tear resistant polyurethane wheels Rear Wheel Lock provided Hand brakes provided Dropback handle provided Portable Wheelchairs Portable Wheelchairs are designed for ease of use and are made from durable material. These wheelchair are often foldable and are easier to store than conventional or custom ramps. They are perfect for both manual and electric wheelchairs, as w

Dr Nik Kotecha OBE, chairman of Morningside Pharmaceuticals and the Randal Charitable Foundation, has won the Distinguished Alumni Award at Imperial College London's Alumni Awards 2022. The annual awards honour outstanding alumni who have demonstrated sustained excellence in their personal and professional achievements and have made a substantial impact on society. Dr Kotecha, who founded Morningside in 1991, which manufactures and supplies generic and branded medicines to the UK and globally, said: "I'm thrilled to be honoured by the university in this way. "As a child growing up in Leicester my family had very little, but I was fortunate to be given opportunities to gain a good education. After finishing my degree in Newcastle; Professor Steve Ley FRS at Imperial College took a chance in accepting me into his eminent group and this really was the opportunity I needed to forge a career.

Loughborough-based generic and branded pharmaceutical manufacturer Morningside Pharmaceuticals has donated almost 60,000 packs of essential medicines to communities impacted by the war in Ukraine. The donation, which includes 1.29 million doses, was made after the company's founder and chairman, Dr Nik Kotecha OBE, spoke with the Ukrainian ambassador to the United Kingdom, Vadym Prystaiko, at a business event in London. Dr Kotecha, who was also recently appointed a deputy lieutenant of Leicestershire, said: "The heartbreaking situation in Ukraine has touched us all, and like so many people in the United Kingdom, we've been keen to do everything we can to help the victims of this terrible conflict." The large shipment of medicines has been transported in a secure and temperature controlled environment via Morningside's logistics partner to the embassy's distribution hub in Poland. From there the medicines will be supplied to hospitals, healthcare centres and patients throughout Ukraine including the regions hardest hit by the Russian invasion.

Pharmaceutical companies AbbVie and Eli Lilly have withdrawn from Britain's voluntary medicines pricing agreement, an industry body said on Monday. Companies are increasingly arguing that it is no longer possible to justify the UK's "voluntary scheme" to global boardrooms and investors as repayment rates in 2023 have surged to 26.5 per cent of revenue, the Association of the British Pharmaceutical Industry (ABPI) said in a statement. "The current scheme has harmed innovation, with costs spiralling out of control, and the UK falling behind other major countries to be left as a global outlier," said Laura Steele, president and general manager for Eli Lilly's Northern Europe division. ABPI said it was seeking early talks with the government to set out a new future settlement. In December, the industry body had said the government raised the amount manufacturers of branded medicines within the voluntary scheme will be required to return to almost £3.3 billion in sales revenue from an earlier amount of £1.8 billion.

The Pharmaceutical Services Negotiating Committee (PSNC) has developed a webtool to help community pharmacy contractors estimate the impact on their payments under the new discount deduction system. The calculator aims to illustrate the changes to discount deduction that a pharmacy could experience during the transition to the new arrangements from October 2022 to January 2024, when the new system will be fully in place. PSNC's calculator requires contractors to input information about their individual pharmacy dispensing mix (i.e. split of reimbursement by appliances, brands and generics) to provide an estimate for the level of impact the new discount deduction system will have. "The impact on individual pharmacies cannot be estimated without using dispensing mix data, meaning that any estimates which do not take this into account will not be reliable," said PSNC. For years many contractors have been frustrated by how discount is applied to their accounts and have often raised concerns about the blanket nature of its application to PSNC.

The British Generic Manufacturers Association (BGMA) has published a positioning paper which sets out the objectives that need to be delivered through the next Voluntary Pricing and Access Scheme (VPAS) on Thursday (15 June). The paper details how a financially sustainable VPAS can support widened medicines access to patients. VPAS is an agreement between the Department of Health and Social Care (DHSC), NHS England and The Association of the British Pharmaceutical Industry (ABPI). The scheme aims to limit increases in spending on branded medicines to no more than 2% per year via a rebate system which is charged on companies' sales revenues. Two years ago, the rate was 5.1% but for 2023 it has soared to 26.5%. Last year, the association had raised concerns over the rise in the VPAS rate for 2023 to 26.5 per cent. "The rocketing rate is in large part due to the growth in spend in on-patent medicines since 2019. Looking at the four completed years of the current VPAS scheme, data shows that the average annual growth rate for on-patent medicine sales value from 2019-22 was 18% compared to just 2% for off-patent products," said the association.

The British scientists behind one of the major therapeutic Covid-19 trials have turned their focus to treatments for monkeypox, a viral disease that has been labelled a global health emergency by the World Health Organization. The team from Oxford University behind the so-called RECOVERY trial - which honed in on four effective Covid treatments - on Tuesday unveiled a new trial, dubbed PLATINUM, to confirm whether Siga Technologies' tecovirimat is an effective treatment for monkeypox. Although there are vaccines developed for the closely related smallpox that can reduce the risk of catching monkeypox, there are currently no treatments that have been proven to help hasten recovery in those who develop the disease. The UK has over 3,000 confirmed cases of monkeypox. The virus is transmitted chiefly through close contact with an infected person. It typically causes mild symptoms including fever, rash, swollen lymph nodes and pus-filled skin lesions. Severe cases can occur, though people tend to recover within two to four weeks. Siga's drug, branded Tpoxx, has been cleared to treat diseases caused by the family of orthopoxvirus that includes smallpox, monkeypox and cowpox by the European Union and United Kingdom, but due to limited trial data it is generally only used in severe cases in Britain.

Community pharmacists are readily accessible healthcare providers and medicine experts in the community setting and their counsel is often sought by patients and consumers on a number of subjects including the use of dietary supplements. Their role in the sale of and advice regarding natural health and drug alternatives has never been more relevant. The recent National Health Service (NHS) Interim People Plan calls for the NHS to put all staff front and centre of the way it operates and identifies pharmacists as a critical part of multidisciplinary teams, providing care across a wide range of increasingly complex patient needs. Despite existing demand to counsel patients on a vast range of medicines, more and more consumers are looking to their pharmacist to support and enhance their knowledge regarding the relevance of a growing range of supplementary nutrients now available. Nutritional supplementation is increasingly becoming the consumer's first choice for 'drug free' treatment or natural prevention that provides a true sense of taking control, which the prescription process often denies them. The vast and growing depository of information on the internet is certainly fuelling this, but as much of this is brand derived content, information, it can often be generic with a 'one size fits all' marketing message.

The Department of Health of Social Care (DHSC) has re-determined that all six Madopar (Co-beneldopa) preparations meet the special container criteria as outlined in Part II Clause 10 of the Drug Tariff. "The NHS dictionary of medicines and devices (dm+d) has now been updated with special container status applied to the complete pack sizes of all Madopar preparations," said PSNC. "The special container rules apply immediately to all branded or generically written prescriptions for Madopar dispensed from December 2022 onwards." The following products will be treated as special containers for prescriptions dispensed from December 2022 onwards:

Aspire Pharma Limited, a leading UK provider of niche generic and branded medicines, on Monday, announced that it has successfully acquired Cenoté Pharma as part of the company's ongoing strategy to supplement its organic growth through acquisitions and strategic partnerships. Cenoté Pharma is a UK-based pharmaceutical company that specialises in addressing carnitine deficiencies. Carnitine is an amino acid derivative whose insufficiency can impair the metabolism of essential tissues, such as those of the liver, heart and muscles. While the exact prevalence of systemic primary carnitine deficiency (SPCD) remains uncertain and varies depending on ethnicity, the estimated prevalence is 1 in 20,000 to 1 in 70,000 newborns in Europe and the USA, as stated by Aspire Pharma in its press release. Aspire CEO Richard Condon expressed enthusiasm about the addition of a new therapy area into the company's portfolio. "This acquisition underscores our commitment to advancing the science and treatment options for vulnerable patient groups," he said.

Indian multinational pharmaceutical company, Dr. Reddy's Laboratories has made its entry into the UK consumer health market with the launch of an over-the-counter allergy medication. Histallay (Fexofenadine Hydrochloride 120 mg tablets) is the company's first general sale list (GSL) product introduced in the UK market. Previously classified as a Prescription Only Medicine (POM), Dr. Reddy's Fexofenadine 120 mg is now available without prescription, under the brand name 'Histallay'. This allows people with allergic seasonal rhinitis (hay fever) to get direct access to the product via retail outlets such as pharmacies and supermarkets in the UK.

The World Health Organization (WHO) issued a warning on Thursday regarding falsified semaglutide medications used for treating type 2 diabetes and obesity in select countries. This WHO Medical Product Alert addresses three falsified batches of the specific brand Ozempic that were detected in Brazil (October 2023), the United Kingdom and Northern Ireland (October 2023), and the United States (December 2023). These falsified semaglutide products were distributed through the regulated supply chain. Novo Nordisk, the genuine manufacturer of Ozempic, confirmed that the three products mentioned in the alert are falsified and were not produced by the company. Healthcare professionals, regulatory authorities and the public are advised to remain vigilant regarding these falsified batches of medicines. Dr Yukiko Nakatani, WHO Assistant Director-General for Access to Medicines and Health Products, urged stakeholders to stop any usage of suspicious medicines and report them to relevant authorities.

Pharmacy2U has recently acquired LloydsDirect in a confidential deal, bringing together two of the UK's foremost online pharmacies. Over time, both entities will integrate their operations under the Pharmacy2U brand, the companies said in a joint statement. The two businesses complement each other effectively, and their teams will now work closely together to uphold the patient-centric approach and service quality for which both are known individually, the statement added. However, there is currently limited clarity regarding the sale process and its impact on Lloyds staff. According to NHS Business Services Authority data from PharmData, Pharmacy2U dispensed 1,528,436 items in June 2023, while LloydsDirect, previously owned by LloydsPharmacy, dispensed 1,142,891 items. This positions them as the top two online prescription pharmacies for items dispensed, with Well.co.uk in third place at 128,691 items.

The British Generic Manufacturers Association (BGMA) has elected Matthew Salzmann, UK Country Manager at Viatris, as its new Vice-Chair with immediate effect. He will replace the current chair of the BGMA, Diane DiGangi-Trench, who is the UK country head for Sandoz. Salzman, who is originally from Australia, has served approximately 1 billion patients worldwide last year as the UK Country Manager at Viatris, a global pharmaceutical company operating in 165 countries. In his role as BGMA Vice-Chair, Salzmann would focus on working in partnership with key stakeholders - the NHS, healthcare professionals, policy makers, clinical societies, patient associations, academia - to ensure access to affordable and sustainable medicines for patients and the NHS.

Brits are increasing relying on over-the-counter (OTC) medicines to prevent or treat common ailments, as the 'care at home trend' has become prominent amongst UK households following the COVID-19 pandemic. Almost three-quarters of Brits (71 per cent) now choose to treat minor ailments at home rather than visit their GP or pharmacist, according to new research. The self-care message promoted by the government and NHS during the pandemic has led to a new generation of consumers who continue to take control of their own health and treat minor ailments themselves. Additionally, the research, commissioned by Lanes Health, revealed that public awareness about preventative treatment has increased, with 70 per cent of Brits claiming that they do their best to prevent the spread of common illnesses since the pandemic.

Lightweight travel wheelchair is a Transport Wheelchair that has a lightweight frame and many features that are common on Transporters.Light travel wheelchairs are great for road trips and travel tours, you can go anywhere with a Travel chair, the frame is light and easy to fold and store, this type of wheelchair fits easily into the trunk of your car, or if you are traveling by plane, bus, or train. We provide Lightweight Travel Wheelchair that are dependable and easy to carry or fold, our Transport Wheelchair Series includes travel wheelchairs that have many unique features. We also carry the original and upgraded "Airplane Wheelchair", which is specifically used for plane travel, meaning that it was designed to fit in an airplane, through the aisles and through the doors, and through the bridge.

Transport chairs, also known as companion wheelchairs, have four small wheels instead of two small and two large. A transport chair is designed to only be push by caregiver, other common names are 'companion chair' or 'rollabout chair'. A huge variety of different widths and weight capacities are available. A transport wheelchair is a mobility chair designed for convenience, short-distance use and easy handling by a caregiver. Lightweight and foldable, these wheelchairs are easily moved and typically fit in the trunk of most vehicles. There is even a model designed to fold into a bag to be carried over the shoulder. They are much smaller than standard manual wheelchairs and similar in size to the front wheels. Without large rear wheels, the user must rely on someone else to push the chair, which is why the transport chair is often referred to as a companion wheelchair. Karma Travel Wheelchair KM TV 20.2: Karma Travel Wheelchair KM TV 20.2 - 606 T-6 aircraft-grade aluminum-alloy frame provides incredible strength. Easy-to-fold in three seconds. Karma Travel Wheelchair KM TV 20.2 Features: Type: Travel Wheelchair T-6 aircraft-grade aluminum Secure brake improve safety Padded flip back armrest PU front caster & rear wheel Karma Travel Wheelchair KM TV 20.2 Measurements: Weight: 8.9kg Seat width: 39.5cm Tyre: PU front casters and rear wheels Capacity: 100kg Folded size: (L/W/H): 610mm x 350mm x710mm. Ultra Lightweight Wheelchair: Its compact design and feather light weight makes it suitable for people on the go. Ultra Lightweight Wheelchair Specifications: Frame Style : Foldable Frame Material : Aluminium (Light weight) Rear wheel to wheel width in open position (inches) : 20" Handle to Handle : 16" Seat Width (inches): 13" Rear Wheel Size: 7" Front Wheel Size: 5" Seat to floor height (inches): 19" Seat Depth (inches): 13" Back height (inches): 16" Total height (inches): 35" Max User Weight Capacity (kgs): 80 k.g. Net Weigh